Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05483868

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Led by Aura Biosciences · Updated on 2026-04-15

55

Participants Needed

17

Research Sites

231 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.

CONDITIONS

Official Title

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 18 years and older with a histopathological diagnosis of non-muscle invasive bladder cancer (NMIBC) of any grade
  • For first diagnosis of NMIBC, confirmation by biopsy within 6 months before screening is required
  • For recurrent NMIBC, current lesion must appear as NMIBC with histopathologic confirmation within last 24 months
  • Participants with low-grade intermediate-risk NMIBC meeting specific criteria such as multifocal low-grade Ta, solitary low-grade Ta larger than 3 cm, or low-grade Ta with prior recurrence within 1 year
  • Participants with high-risk NMIBC including Ta high-grade papillary disease or T1 papillary disease with or without carcinoma in situ
  • Participants may be BCG-naive or have received prior BCG treatment for high-risk or intermediate-risk NMIBC, excluding BCG-refractory patients
  • No evidence of current or prior metastatic urothelial carcinoma
  • Adequate bone marrow, kidney, and liver function
Not Eligible

You will not qualify if you...

  • Presence of any other malignancy requiring active treatment unless approved by the Investigator and Medical Monitor
  • Use of investigational drugs or devices within 30 days or 5 half-lives before first visit or concurrent enrollment in another investigational trial
  • Active bacterial, fungal, or viral infections; all previous infections must be resolved and no systemic anti-infective agents currently used
  • Active autoimmune disease, chronic inflammatory conditions, or conditions requiring systemic immunosuppressants or steroids such as organ transplant or bone marrow transplant
  • Chronic active hepatitis B or C infection or HIV infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Arkansas Urology

Little Rock, Arkansas, United States, 72211

Terminated

2

Tower Urology

Los Angeles, California, United States, 90048

Actively Recruiting

3

Saint John's Cancer Institute

Santa Monica, California, United States, 90404

Actively Recruiting

4

Montefiore Medical Center

The Bronx, New York, United States, 10461

Actively Recruiting

5

Carolina Urologic Research Center

Myrtle Beach, South Carolina, United States, 29272

Actively Recruiting

6

Urology Associates, P.C.

Nashville, Tennessee, United States, 37209

Suspended

7

Urology Clinics of North Texas

Dallas, Texas, United States, 75251

Actively Recruiting

8

Baylor College of Medicine

Houston, Texas, United States, 77030

Actively Recruiting

9

The University of Texas San Antonio

San Antonio, Texas, United States, 78229

Actively Recruiting

10

Urology San Antonio/USA Clinical Trials

San Antonio, Texas, United States, 78229

Actively Recruiting

11

The Urology Place

San Antonio, Texas, United States, 78240

Actively Recruiting

12

Westmead Private Hospital

Westmead, New South Wales, Australia, 2145

Actively Recruiting

13

Austin Health

Heidelberg, Victoria, Australia, 3084

Actively Recruiting

14

Warringal Private Hospital

Heidelberg, Victoria, Australia

Actively Recruiting

15

Penninsula Private Hospital

Langwarrin, Victoria, Australia, 3910

Not Yet Recruiting

16

The Royal Melbourne Hospital

Parkville, Victoria, Australia, 3050

Not Yet Recruiting

17

Hollywood Private Hospital

Nedlands, Western Australia, Australia, 6009

Actively Recruiting

Loading map...

Research Team

M

Medical Monitor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

10

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here